KEY POINTS

  • Pfizer is expected to earn $15 billion in 2021 for its Comirnaty vaccine
  • Moderna expects to make $18.4 billion for its mRNA-1237 vaccine
  • The J&J vaccine may earn $10 billion by the end of the year

Johnson & Johnson, Moderna and Pfizer are all set to earn billions from their coronavirus vaccines, according to a report.

The U.S. Centers for Disease Control and Prevention and the Food and Drug Administration have granted emergency use authorization to the COVID-19 vaccines manufactured by Pfizer-BioNTech, Moderna and J&J. The authorization is expected to bring in billions to the three companies, a roundup from Fox Business noted.

Pfizer-BioNTech

Pfizer and BioNTech’s COVID-19 vaccine, referred to as Comirnaty, was the first to receive emergency use approval from the FDA. The vaccine is 95% effective against the novel coronavirus and currently accounts for over 46.8 million of the total doses administered in the country, the CDC’s COVID Data Tracker showed. 

According to Pfizer’s latest earnings report, profits made from the Comirnaty vaccine are split 50-50 with BioNTech. Both companies expect the vaccine to bring in $39 per two doses in the U.S. and $28 in the EU — totaling an estimated $15 billion in 2021. 

Moderna

During its clinical trial, Moderna’s mRNA-1273 vaccine was found to be 94.5% effective against COVID-19. It was the second vaccine to be granted emergency use authorization in the U.S. Currently, Moderna’s vaccine accounts for 44.9 million of the total vaccine doses given out across the nation. 

In the company’s earnings report for the fourth quarter, Moderna said it expects to make $18.4 billion in anticipated product sales related to the vaccine. Two shots of its COVID-19 vaccine costs $30 in the U.S. and $36 in the EU. 

Moderna aims to build a supply of up to 1 billion doses of its mRNA-1273 vaccine in 2021.

Johnson & Johnson

The J&J vaccine, manufactured by Janssen, its pharmaceutical subsidiary, was given emergency-use approval by the CDC and FDA on Feb. 28. 

An FDA analysis found that the J&J vaccine had an efficacy rate of 67% against moderate to severe COVID-19 cases within 14 days after the dose. The efficacy rate goes down to 66% against severe and critical coronavirus cases 28 days after inoculation. 

The J&J vaccine is 77% effective in preventing severe or critical cases of coronavirus occurring at least 14 days after vaccination and 85% effective against severe or critical coronavirus cases at least 28 days after inoculation. 

Johnson & Johnson is expected to earn $10 billion by the end of the year. It had previously reached a $1 billion agreement with the U.S. for 100 million doses of its coronavirus vaccine. 

Each dose of the J&J vaccine costs $10.     

Many job openings have been in positions related to Covid-19 vaccine drives A COVID-19 vaccination is pictured. Photo: AFP / Joseph Prezioso